Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression [Phase 1, Phase 2]

View source ↗

Summary

A2 Biotherapeutics is evaluating A2B395, an allogeneic logic-gated CAR T therapy, in Phase 1/2 trials for solid tumors expressing EGFR and lacking HLA-A*02 expr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Adenocarcinoma
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Rectal Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• A2B395

Snippet

Sponsor: A2 Biotherapeutics Inc. | Conditions: Solid Tumor, Adult, Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING